How to Get Zepbound: LillyDirect, Insurance, and the Compounded Path

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Four access paths: insurance, LillyDirect, retail cash-pay, or compounded tirzepatide
• LillyDirect Self Pay Journey Program offers 2.5 mg vials at $349/month, the lowest manufacturer-direct price for brand tirzepatide
• The December 2024 OSA expansion opened Medicare coverage and additional commercial coverage paths
• Compounded tirzepatide through 503A pharmacies runs $300-$600/month with clinician-documented medical necessity
• Patients can switch from Wegovy to Zepbound without a washout period under clinician supervision

Direct answer

You can get Zepbound through four pathways in 2026. Insurance covers Zepbound for patients with BMI 30+ or BMI 27+ with comorbidity (and now for moderate-to-severe OSA with BMI 30+ under the December 2024 expansion). LillyDirect Self Pay Journey Program offers 2.5 mg single-dose vials at $349/month directly from Eli Lilly. Retail cash-pay for the pen runs around $1,060/month. Compounded tirzepatide through 503A pharmacies typically runs $300-$600/month with clinician-documented medical necessity.

Table of contents

1. The four access paths
2. Path 1: insurance coverage
3. Path 2: LillyDirect Self Pay Journey Program
4. Path 3: retail cash-pay for the pen
5. Path 4: compounded tirzepatide
6. The OSA indication and insurance impact
7. Vials vs. pens: what to know
8. Switching from Wegovy or another GLP-1
9. Common access pitfalls
10. Contrary view: is LillyDirect a sustainable model
11. Decision framework
12. FAQ
13. Sources

The four access paths

Path	Eligibility	Cost	Form Factor
Insurance	BMI 30+ or 27+ with comorbidity; or OSA + BMI 30+	Copay $25-$300/month	Pen
LillyDirect Self Pay	Valid prescription; no insurance restriction	$349/month (2.5 mg vials); scales up	Single-dose vials, self-draw syringe
Retail cash-pay	Valid prescription	~$1,060/month	Pen
Compounded tirzepatide	Clinician-documented medical necessity	$300-$600/month	Vials, varies by pharmacy

Path 1: insurance coverage

Commercial insurance coverage for Zepbound depends on plan benefit design:

• Plans that cover obesity pharmacotherapy: typically require BMI 30+ or 27+ with comorbidity
• Plans with weight-loss carve-outs: may exclude Zepbound entirely
• Plans with step therapy: may require prior trial of phentermine, topiramate, naltrexone-bupropion, or other approved weight-loss medications

Prior authorization documentation typically required:

1. Current BMI calculation with height and weight
2. Comorbidity documentation (lab results, blood pressure, sleep study, ICD-10 codes)
3. Documented prior lifestyle intervention (typically 3-6 months)
4. Sometimes: prior pharmacotherapy trial
5. Confirmation of no contraindications

The OSA pathway is a separate coverage route. Submit the OSA diagnosis (with sleep study results showing AHI 15+ or AHI 5+ with daytime symptoms) and BMI 30+ documentation. Some plans treat this as a distinct prior authorization with different criteria.

Eli Lilly's manufacturer savings card for Zepbound can reduce copays for commercial insurance patients. Cards do not apply to Medicare or Medicaid.

Path 2: LillyDirect Self Pay Journey Program

Eli Lilly launched LillyDirect in early 2024 as a direct-to-consumer cash-pay program for Zepbound. The Self Pay Journey Program offers:

• Single-dose 2.5 mg vials at $349/month with valid prescription
• 5 mg vials at higher pricing (approximately $549/month as of 2025-2026)
• Higher doses (7.5 mg, 10 mg, 12.5 mg, 15 mg) priced higher; check current LillyDirect pricing
• Direct delivery from Eli Lilly's logistics partners
• No insurance involvement

How to enroll:

1. Get a valid Zepbound prescription from a licensed clinician (in-person or telehealth)
2. Visit LillyDirect's enrollment portal
3. Provide prescription, identity verification, payment, and shipping information
4. Vials ship to your address
5. Self-draw medication into a syringe for weekly administration

The vial-syringe format requires more user skill than the pen. Eli Lilly provides written and video guidance on drawing and injecting from vials. Patients uncomfortable with syringes may prefer the pen path through insurance or retail cash-pay.

Path 3: retail cash-pay for the pen

If you want the pen form factor without insurance, you can fill at a retail pharmacy paying cash. Retail prices in 2026:

• CVS, Walgreens, Walmart: roughly $1,050-$1,100 per month for the pen
• Costco, Sam's Club (members): roughly $950-$1,050 per month
• Independent pharmacies: variable
• GoodRx and coupon programs: typically $1,000-$1,100 per month

The retail pen format is the same product available through insurance with insurance copays. The price difference is primarily because cash-pay does not receive plan-negotiated discounts.

Path 4: compounded tirzepatide

Compounded tirzepatide is prepared by state-licensed 503A pharmacies in response to individual prescriptions. The October 2024 FDA declaration that the tirzepatide shortage was resolved added restrictions on bulk-quantity compounding.

Current compounded tirzepatide path:

1. Patient enrolls through a platform partnering with a 503A pharmacy
2. Licensed clinician evaluates and documents medical necessity
3. Prescription routes to a state-licensed 503A pharmacy
4. Pharmacy prepares medication and ships
5. Ongoing clinical follow-up

Pricing: typically $300-$600 per month depending on dose, pharmacy, and platform. Some platforms charge flat rates; others scale with dose.

Compounded tirzepatide is not FDA-approved and is not interchangeable with brand Zepbound or Mounjaro. Formulations vary by compounding pharmacy in concentration, vial size, and inactive ingredients. Patient outcomes with compounded products are not directly comparable to clinical trial data for brand tirzepatide.

The OSA indication and insurance impact

The December 20, 2024 FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity created new coverage pathways. The clinical criteria:

• Adult age 18+
• Moderate-to-severe OSA (AHI 15+/hour or AHI 5+/hour with daytime symptoms)
• BMI 30+ (obesity)

Insurance coverage impact:

• Medicare Part D: previously excluded all obesity-only drugs; now covers Zepbound for OSA indication
• Commercial insurance: many plans that excluded obesity drugs now cover under the OSA pathway
• Documentation needed: sleep study report showing AHI threshold, BMI confirmation, sometimes documented PAP therapy trial

The SURMOUNT-OSA trial (Malhotra et al. 2024, NEJM) supported this expansion with AHI reductions of approximately 25-30 events per hour in the tirzepatide arms versus minimal change in placebo. Roughly half of tirzepatide patients met criteria for OSA remission.

Vials vs. pens: what to know

The form factor matters more than it sounds:

Feature	Pen	Vial
Form	Pre-loaded auto-injector	Glass vial requiring syringe draw
Ease of use	High (single button click)	Moderate (drawing skill required)
Storage	Refrigerated; can be at room temperature briefly	Refrigerated
Distribution	Retail pharmacy, insurance, telehealth shipment	LillyDirect, some compounding
Price (cash-pay)	~$1,060/month	$349/month (2.5 mg via LillyDirect)
Dosing flexibility	Fixed dose per pen	Theoretical micro-dose flexibility

Patients comfortable with syringes who prioritize price often choose vials. Patients prioritizing ease and minimal handling typically prefer pens. Either delivers the same medication.

Switching from Wegovy or another GLP-1

Common switching scenarios:

Wegovy to Zepbound. Patients with inadequate weight loss on maximum Wegovy (2.4 mg) sometimes switch. Tirzepatide produces greater mean weight loss in head-to-head data (SURMOUNT-1 ~22.5% at 15 mg vs. STEP 1 ~14.9% at 2.4 mg). Switch typically starts at Zepbound 2.5 mg or 5 mg with standard titration.

Mounjaro to Zepbound. Same active ingredient. Switching is often administrative (insurance coverage change, indication change from diabetes to obesity). Dose typically continues at the same level.

Compounded tirzepatide to brand Zepbound. Patients sometimes switch when insurance opens coverage, or for the predictable formulation of FDA-approved product. Dose continues at the same level under clinician supervision.

Brand Zepbound to compounded tirzepatide. Patients sometimes switch for cost reasons. Awareness of formulation differences and ongoing clinician supervision are important.

No washout period is required between these medications because their mechanisms overlap but differ.

Common access pitfalls

Prior authorization denials. Insurance may deny initial prior authorization for missing documentation, insufficient BMI, or step therapy requirements not yet met. Most denials can be appealed with additional documentation or a clinician letter of medical necessity.

Step therapy traps. Some plans require prior trials of phentermine, topiramate, naltrexone-bupropion, or other weight-loss medications. Document any past attempts thoroughly to avoid having to repeat them.

OSA documentation gaps. The OSA pathway requires a sleep study report. If you have OSA but no recent sleep study, getting one may add weeks. Older sleep studies may not satisfy all insurance plans.

Vial handling errors. Patients new to syringes may waste medication through poor drawing technique or air bubbles. Watch Eli Lilly's instructional videos before your first dose.

Counterfeit gray market. Some online sources offer "Zepbound" or "tirzepatide" at suspiciously low prices. The FDA has documented counterfeit semaglutide products; tirzepatide counterfeits also exist. Use only U.S.-licensed pharmacies.

Compounding pharmacy variation. Compounded tirzepatide formulations differ between pharmacies. If switching compounding pharmacies, expect potential changes in injection volume, vial concentration, or tolerability.

Contrary view: is LillyDirect a sustainable model

Eli Lilly's LillyDirect Self Pay Journey Program represents a notable departure from traditional pharmaceutical distribution. The model has implications:

Arguments that it's sustainable:

• Eli Lilly captures direct margin without pharmacy benefit manager middlemen
• The $349/month vial price is achievable because the vial form factor is cheaper to produce than the pen
• Direct relationship with patients enables better adherence support and refill management
• Reduces pressure on retail pharmacy distribution constraints

Arguments that it's unsustainable or problematic:

• If insurance coverage expands, patients may shift back to insurance-covered pens, reducing direct-pay volume
• Vial format requires patient skill that some users lack, limiting market
• Direct-to-consumer pharmaceutical distribution may face regulatory scrutiny if quality issues arise
• Manufacturer-direct pricing undermines insurance negotiation and may affect long-term coverage

The pattern in 2025-2026 suggests Eli Lilly is committed to the model. The expansion to higher doses and continued marketing investment imply LillyDirect is positioned as a long-term access channel, not a temporary supply-relief measure.

Whether Novo Nordisk launches a comparable program for Wegovy or Ozempic remains an open question. The competitive pressure exists, but Novo Nordisk has not made similar direct-to-consumer moves through May 2026.

Decision framework

You have BMI 30+ and good obesity insurance coverage: Path 1 (insurance). Pen format, standard distribution. Document lifestyle intervention for prior authorization.

You have OSA with BMI 30+ and Medicare: Pursue Path 1 via the OSA indication. Submit sleep study results.

You meet criteria but insurance does not cover: Path 2 (LillyDirect) if comfortable with vials, Path 4 (compounded) for lower-cost alternative.

You want the pen and have no insurance: Path 3 (retail cash-pay) at roughly $1,060/month.

You want to minimize cost: Path 4 (compounded tirzepatide) at $300-$600/month, or Path 2 (LillyDirect 2.5 mg vials) at $349/month.

You are switching from Wegovy: Choose the path your insurance and clinician favor. Start at Zepbound 2.5 mg or 5 mg with standard titration.

FAQ

How do I get Zepbound? Four paths: insurance with BMI 30+ or OSA pathway, LillyDirect at $349/month for vials, retail cash-pay around $1,060/month, or compounded tirzepatide at $300-$600/month.

What is LillyDirect and how do I use it? Eli Lilly's direct-to-consumer cash-pay program. Order 2.5 mg single-dose vials at $349/month with valid prescription. Higher doses scale up.

Does insurance cover Zepbound? Varies by plan. BMI 30+ or 27+ with comorbidity for obesity pathway. OSA pathway opened December 2024 for moderate-to-severe OSA with BMI 30+.

How much does Zepbound cost? $349/month for 2.5 mg vials through LillyDirect, ~$1,060/month for the pen at retail, $25-$300/month with insurance, $300-$600/month for compounded tirzepatide.

What is the difference between vials and pens? Pens are pre-loaded auto-injectors; vials require drawing into a syringe. Same active ingredient.

Can I get Zepbound through telehealth? Yes, in all 50 states with properly licensed providers.

Does Medicare cover Zepbound? Yes, for the OSA indication. Not for obesity alone.

Can I switch from Wegovy to Zepbound? Yes, with clinician supervision. Start at Zepbound 2.5 mg or 5 mg; no washout required.

Sources

1. FDA. Zepbound Prescribing Information, including OSA Indication. Current revision 2025.
2. Eli Lilly. LillyDirect Self Pay Journey Program: Eligibility and Pricing Page. Updated 2025-2026.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
4. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM. 2024.
5. FDA. Press Release: Zepbound Approved for Obstructive Sleep Apnea in Adults with Obesity. December 2024.
6. Centers for Medicare and Medicaid Services. Medicare Part D Coverage Update: OSA Indication. 2025.
7. FDA. Drug Shortages: Tirzepatide Shortage Resolution. October 2024.
8. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
9. American Association of Sleep Medicine. Clinical Guidelines for OSA Diagnosis and Management. 2024 update.
10. State Boards of Pharmacy. 503A Compounding Regulations Survey. NABP, 2025.
11. Eli Lilly. Zepbound Manufacturer Savings Card: Terms. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed clinicians and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. Clinical decisions including medication selection and dosing are made by independent licensed providers.

Compounded Medication Notice. Compounded tirzepatide is prepared by a state-licensed 503A pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand Zepbound or Mounjaro. Formulations vary between compounding pharmacies.

Results Disclaimer. Pricing cited reflects approximate market rates as of May 2026 and may change. Trial outcomes (SURMOUNT-1, SURMOUNT-OSA, SURMOUNT-4) reflect average results in trial populations. Individual outcomes depend on adherence, baseline weight, and concurrent therapy.

Trademark Notice. Zepbound, Mounjaro, and LillyDirect are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are trademarks of Novo Nordisk A/S. GoodRx is a registered trademark of GoodRx Holdings. FormBlends is not affiliated with these companies.